20170406 Telix Logo.png
Telix and SHINE partner for Lutetium-177 Supply
10. Februar 2022 16:09 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a new global clinical supply agreement with...
20170406 Telix Logo.png
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement
08. Februar 2022 17:27 ET | Telix Pharmaceuticals Limited
MELBOURNE and LIEGE, Belgium, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a global clinical supply agreement with Berlin-based...
20170406 Telix Logo.png
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
26. Januar 2022 16:51 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s...
20170406 Telix Logo.png
Telix Expands Prostate Cancer Activity with GenesisCare Collaboration
18. August 2021 18:47 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today releases details of two ancillary studies under the ProstACT program...
20170406 Telix Logo.png
Telix and Merck to Commence Pan-Cancer Clinical Combination Studies
17. August 2021 21:03 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has entered into a pan-cancer clinical collaboration...
20170406 Telix Logo.png
Telix and Merck KGaA, Darmstadt, Germany, to Commence Pan-Cancer Clinical Combination Studies
17. August 2021 21:02 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has entered into a pan-cancer clinical collaboration...
20170406 Telix Logo.png
Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
09. Mai 2021 19:13 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, May 09, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has been granted Human Research Ethics Committee (HREC)...
20170406 Telix Logo.png
Telix Pharmaceuticals and GenesisCare Commence ENHANCING Prostate Cancer Clinical Study
07. August 2019 20:00 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and SYDNEY, Australia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on...